Tags : FYB201


Formycon and Bioeq Report Submission of BLA to the US

Shots: Formycon and partner Bioeq have submitted a BLA for FYB201 (biosimilar referencing Lucentis) to the FDA Lucentis is a mAb fragment used to treat various types of macular-degenerative diseases and other serious eye diseases. If approved, Coherus will commercialize FYB201 in the US Currently, Formycon has four biosimilars while Coherus also has a biosimilar […]Read More


Bioeq Collaborates with Teva to Commercialize FYB201 (biosimilar, ranibizumab)

Shots: Polpharma reported that its JV with Santo Holding, Bioeq has concluded a commercial partnership with Teva for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis) in the EU, Canada, Israel, and New Zealand The agreement complements an existing agreement concluded with Coherus for the commercialization of the biosimilar in the US FYB201 was […]Read More


Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201

Shots: The companies collaborated to commercialize Bioeq’s FYB201 (biosimilar referencing Lucentis) in the EU, Canada, Israel & New Zealand Bioeq will be responsible for the development, registration, and supply of the biosimilar while Teva will be responsible for commercializing the product. The companies will share revenue from the commercialization of the biosimilar The collaboration will […]Read More